Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib in Chronic Spontaneous Urticaria (CSU)
NCT05030311Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of remibrutinib in chronic spontaneous urticaria (CSU), sponsored by Novartis. Started Nov 2021; status: completed.
02
Drugs
remibrutinib
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT05030311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05030311.